Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
"There is actually very decent growth in the Danish economy already, but it's pretty narrow — it's driven by Novo Nordisk and the other pharmaceutical companies," Olsen said last week.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback